52121-36-5

Usage

Uses

Used in Organic Synthesis:
3-Bromo-4-ethylbenzenamine is used as a key intermediate in the synthesis of various organic compounds for [application reason]. Its unique structure with a bromine atom and an ethyl group provides versatility in chemical reactions, making it a valuable component in the creation of new molecules.
Used in Research Labs:
3-Bromo-4-ethylbenzenamine is used as a research chemical for [application reason]. Its properties and reactivity are studied to understand its potential applications in the development of new materials and compounds.
Used in Industrial Labs:
3-Bromo-4-ethylbenzenamine is used as a raw material in the production of specialty chemicals for [application reason]. Its presence in the synthesis process can lead to the creation of novel products with specific properties required by various industries.

Upstream product

• 20191-74-6 2-ethyl-5-nitroaniline 
• 100-12-9 4-ethylnitrobenzene 
• 52121-34-3 2-bromo-1-ethyl-4-nitrobenzene 

Downstream Products

• 52121-38-7 3-bromo-4-ethyl-6-nitroaniline 
• 186666-73-9 (5-Bromo-4-ethyl-2-nitro-phenylamino)-acetic acid ethyl ester 
• 186666-72-8 N-(5-Bromo-4-ethyl-2-nitro-phenyl)-2,2,2-trifluoro-acetamide 
• 1445789-64-9 diethyl 2-((3-bromo-4-ethylphenylamino)methylene)malonate 
• 1445789-74-1 C₃₁H₃₃N₅O₅ 
• 1445789-70-7 methyl 3-(7-bromo-3-carbamoyl-6-ethylquinolin-4-ylamino)-5-cyclopentylbenzoate 
• 1445786-78-6 3-((3-carbamoyl-7-(2,4-dimethoxypyrimidin-5-yl)-6-ethylquinolin-4-yl)amino)-5-cyclopentylbenzoic acid 
• 355013-43-3 5-(3-bromo-4-ethyl-anilino)-8-[(6-methoxy-pyridin-3-yl)-methyl]-[1,6]naphthyridine 
• 147150-13-8 6-bromo-5-ethylanthranilic acid 
• 852946-96-4 2-bromo-1-ethyl-4-methoxybenzene 
• 878487-84-4 α-(2-ethyl-5-methoxyphenyl)acetophenone 

Relevant academic research and scientific papers

PHARMACEUTICAL COMPOSITION AND APPLICATION REPLACING QUINOLONE DERIVATIVE, PHARMACEUTICAL ACCEPTABLE SALT, OR STEREOISOMER

Provided are a substituted quinolone derivative as shown by formula (I), or a pharmaceutically acceptable salt and a prodrug molecule thereof, and a pharmaceutical composition thereof, as well as the use of same in preparing drugs for the prevention and treatment of a tumor. The quinolone derivative, salt, prodrug molecule, and pharmaceutical composition thereof can be used as a protein kinase inhibitor, which is effective in inhibiting the activity of AXL protein kinase, and is capable of inhibiting the proliferation, migration and invasion of various tumor cells; and can be used in the preparation of anti-tumor drugs, especially drugs for treating hyperproliferative diseases such as a tumor in human beings and other mammals.

CHEMICAL COMPOUNDS

The invention is directed to substituted quinoline derivatives. Specifically, the invention is directed to compounds according to Formula (I): wherein R1, R2, R3; R4; and R5 are defined herein. The compounds of the invention are inhibitors of lactate dehydrogenase A and can be useful in the treatment of cancer and diseases associated with tumor cell metabolism, such as cancer, and more specifically cancers of the breast, colon, prostate and lung. Accordingly, the invention is further directed to pharmaceutical compositions comprising a compound of the invention. The invention is still further directed to methods of inhibiting lactate dehydrogenase A activity and treatment of disorders associated therewith using a compound of the invention or a pharmaceutical composition comprising a compound of the invention.

COMPOSITIONS FOR TREATMENT OF CYSTIC FIBROSIS AND OTHER CHRONIC DISEASES

The present invention relates to pharmaceutical compositions comprising an inhibitor of epithelial sodium channel activity in combination with at least one ABC Transporter modulator compound of Formula A, Formula B, Formula C, or Formula D. The invention also relates to pharmaceutical formulations thereof, and to methods of using such compositions in the treatment of CFTR mediated diseases, particularly cystic fibrosis using the pharmaceutical combination compositions.

Modulators of ATP-binding cassette transporters

Compounds of the present invention and pharmaceutically acceptable compositions thereof, are useful as modulators of ATP-Binding Cassette (“ABC”) transporters or fragments thereof, including Cystic Fibrosis Transmembrane Conductance Regulator (“CFTR”). The present invention also relates to methods of treating ABC transporter mediated diseases using compounds of the present invention.

Electronic effects of ring substituents on triplet benzylic biradicals

UV irradiation of α-(o-alkylphenyl)acetophenones with a methoxy or cyano substituent para to the o-alkyl group of the α-aryl ring has revealed that a methoxy group slightly increases the stereoselectivity but not the quantum yield of indanol formation, whereas a cyano group greatly lowers both diastereoselectivity and quantum efficiency, confirming the likelihood that hydrogen-bonding of the hydroxy group to the α-phenyl ring plays an important role in the cyclization of the photogenerated triplet 1,5-biradical intermediates.

Pyridine derivatives inhibiting angiogenesis and/or vegf receptor tyrosine kinase

The invention relates to pyridine derivatives of formula (I), wherein the substituents and symbols are defined as indicated in the description, processes for the preparation thereof, their usage in the preparation of a pharmaceutical composition for the treatment of a disease which responds to an inhibition of angiogenesis, and pharmaceutical compositions containing such compounds.

Triaromatic vitamin D analogues

The invention relates, as novel and useful industrial products, to triaromatic compounds, which are vitamin D analogues, of general formula (I): and also to a method for preparing them and to their use in pharmaceutical compositions intended for use in human or veterinary medicine, or alternatively in cosmetic compositions.

Structure-activity relationships of alkyl- and alkoxy-substituted 1,4- dihydroquinoxaline-2,3-diones: Potent and systemically active antagonists for the glycine site of the NMDA receptor

We report on a series of alkyl- and alkoxy-substituted 1,4- dihydroquinoxaline-2,3-diones (QXs), prepared as a continuation of our structure-activity relationship (SAR) study of QXs as antagonists for the glycine site of the N-methyl-D-aspartate (NMDA) re